These results suggest that NHS–rmIL-12 directly activates T lymphocytes through binding of IL-12R to induce significant tumor growth delay, but they suggest that maximum treatment effect and cure of tumors requires IL-12Rb2 expression in the myeloid compartment. This evidence concerns the gene IL12RB1 and neoplasm.